Endpoints That Matter

July 23, 2020

Parexel’s Andreas Reiff, VP, Global TA Head, Inflammation/Immunology talks with Julie Stover, Senior Director, Solution Consulting, also from Parexel, about her journey being diagnosed with Ankylosing spondylitis (AS) and how capturing meaningful endpoints during the drug development process means a better quality of life for patients like her.

Previous Article
Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients
Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients

Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how bi...

Next Article
Rare disease and orphan drug designations - What you need to know
Rare disease and orphan drug designations - What you need to know

Collectively, rare diseases affect over 30 million Americans.  The Orphan Drug Act (ODA), which provi...

×

Lets start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!